Mylan Stock Price, News & Analysis (NASDAQ:MYL)

$46.51 -0.27 (-0.58 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$46.78
Today's Range$45.69 - $46.63
52-Week Range$29.39 - $47.25
Volume6.32 million shs
Average Volume6.34 million shs
Market Capitalization$25.09 billion
P/E Ratio28.02
Dividend YieldN/A
Beta1.38

About Mylan (NASDAQ:MYL)

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MYL
CUSIP62853010
Phone44-0-17-0785-3000

Debt

Debt-to-Equity Ratio1.05%
Current Ratio1.46%
Quick Ratio0.95%

Price-To-Earnings

Trailing P/E Ratio28.0180722891566
Forward P/E Ratio10.20
P/E Growth1.48

Sales & Book Value

Annual Sales$11.08 billion
Price / Sales2.25
Cash Flow$7.59 per share
Price / Cash6.13
Book Value$20.78 per share
Price / Book2.24

Profitability

Trailing EPS$1.66
Net Income$480 million
Net Margins7.28%
Return on Equity20.63%
Return on Assets7.19%

Miscellaneous

Employees35,000
Outstanding Shares536,440,000

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) issued its quarterly earnings results on Monday, November, 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by $0.10. The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business's revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.38 earnings per share. View Mylan's Earnings History.

When will Mylan make its next earnings announcement?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Mylan.

What guidance has Mylan issued on next quarter's earnings?

Mylan issued an update on its FY18 earnings guidance on Monday, November, 6th. The company provided EPS guidance of $5.40 for the period, compared to the Thomson Reuters consensus estimate of $5.33. Mylan also updated its FY17 guidance to $4.45-4.70 EPS.

Where is Mylan's stock going? Where will Mylan's stock price be in 2018?

17 equities research analysts have issued 12 month target prices for Mylan's shares. Their predictions range from $29.39 to $59.00. On average, they anticipate Mylan's stock price to reach $44.20 in the next twelve months. View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:

  • 1. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "News outlets today reported State attorney generals are seeking to sue Mylan’s president and executive director, Rajiv Malik, as part of a civil investigation, according to Connecticut Attorney General George Jepsen." (10/31/2017)
  • 3. Argus analysts commented, "junior version" (8/22/2017)
  • 4. Mizuho analysts commented, "We were previously modeling 2017 generic Advair sales of $150M ramping to peak sales of $363M in 2020. Without the 2017 contribution we would still fall generally in line with consensus revenue estimates for 2017 (~$12.7B), which is below the mid-point of the guidance range of $12.25-13.75B. It is unclear if Mylan can get its product to the market before year end so it may be more conservative to exclude it for now, though we continue to anticipate its launch next year. While the limited visibility provided on this product may be frustrating to investors, we think that the magnitude of the stock reaction creates a buying opportunity given the small overall contribution from this generic in the near-term. We therefore reiterate our Buy rating and $53 PT. Next Advair-related event: Hikma/Vectura has a May 10 GDUFA date for their own generic Advair, and Hikma indicated that it will be ready to launch immediately after approval. Unlike Mylan’s product, which is hoped to be an AB-rated generic, but also one with brand recognition, Hikma’s generic will not be marketed under a brand name. Hikma mgmt has indicated that its Advair generic will make up the majority of its $120M new-launch guidance in 2017 (assuming one other competitor in the market)." (3/30/2017)
  • 5. Royal Bank of Canada analysts commented, "MYL reported 4Q today and hosted what we thought was an upbeat 2017 Investor Day showcasing an impressive pipeline. While overall performance remains stable avoiding headwinds felt by smaller peers, 2017 EPS and stock upside will be linked to a few key approvals along with business development. No change to Sector Perform rating but our price target moves up to $48 on higher EPS...First time 2017 guidance was favorable but there are a lot of moving parts to consider. We said going in that an ambitious 2017 outlook wouldn't be enough unless it came with a solid 4Q result. While visibility into specific 4Q drivers was not as high as we would like, it did provide some comfort around MYL's overall stability in a challenging generic environment. The 2017 guidance range of $5.15 to $5.55 captured consensus and helped drive the +7% move in the stock today, but focus will now shift to several important drivers to get there. As we suspected, that range includes risk-adjusted generic Advair, generic Copaxone 20/40mg as well as some incremental business development. Epipen profit impact was quantified and the driver of the slight gross margin moderation. Our new forecasts for 2017-19E move higher and are now $5.30, $5.75 and $6.12 (the $6.00 MYL EPS target in 2018E remains). Based on our new 2018 EBITDA, MYL trades at 9.1x EV/EBITDA - above historical pre-2014 levels." (3/2/2017)

Are investors shorting Mylan?

Mylan saw a increase in short interest in the month of December. As of December 15th, there was short interest totalling 23,243,650 shares, an increase of 10.0% from the November 30th total of 21,122,199 shares. Based on an average daily trading volume, of 8,674,077 shares, the short-interest ratio is currently 2.7 days. Currently, 4.6% of the company's stock are short sold.

Who are some of Mylan's key competitors?

Who owns Mylan stock?

Mylan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.36%), Hexavest Inc. (0.27%), Nisa Investment Advisors LLC (0.03%), Livforsakringsbolaget Skandia Omsesidigt (0.02%), Exxonmobil Investment Management Inc. TX (0.02%) and Oakbrook Investments LLC (0.01%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Joseph C Md Maroon, Laboratories Abbott, Mark W Parrish, Melina E Higgins, Rajiv Malik, Robert J Cindrich, Robert J Coury and Wendy Cameron. View Institutional Ownership Trends for Mylan.

Who sold Mylan stock? Who is selling Mylan stock?

Mylan's stock was sold by a variety of institutional investors in the last quarter, including Exxonmobil Investment Management Inc. TX, Livforsakringsbolaget Skandia Omsesidigt and DAVENPORT & Co LLC. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Laboratories Abbott and Rajiv Malik. View Insider Buying and Selling for Mylan.

Who bought Mylan stock? Who is buying Mylan stock?

Mylan's stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Schwab Charles Investment Management Inc., Hexavest Inc., Oakbrook Investments LLC, Charter Trust Co. and Creative Planning. Company insiders that have bought Mylan stock in the last two years include Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich and Wendy Cameron. View Insider Buying and Selling for Mylan.

How do I buy Mylan stock?

Shares of Mylan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of Mylan stock can currently be purchased for approximately $46.51.

How big of a company is Mylan?

Mylan has a market capitalization of $25.09 billion and generates $11.08 billion in revenue each year. The company earns $480 million in net income (profit) each year or $1.66 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000.


MarketBeat Community Rating for Mylan (MYL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  575 (Vote Outperform)
Underperform Votes:  408 (Vote Underperform)
Total Votes:  983
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mylan (NASDAQ:MYL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.592.652.592.75
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
2 Strong Buy Rating(s)
Consensus Price Target: $44.20$42.09$40.63$51.28
Price Target Upside: 5.52% downside6.58% upside5.49% upside32.33% upside

Mylan (NASDAQ:MYL) Consensus Price Target History

Price Target History for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Wells Fargo & CoReiterated RatingMarket Perform$33.00 -> $43.00LowView Rating Details
1/11/2018Goldman Sachs GroupBoost Price TargetBuy$46.00 -> $52.00HighView Rating Details
1/4/2018CitigroupReiterated RatingBuy -> Buy$48.00 -> $58.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageMkt Perform -> Market Perform$44.00LowView Rating Details
12/26/2017Cantor FitzgeraldSet Price TargetHold$41.00LowView Rating Details
12/12/2017GuggenheimInitiated CoverageBuy -> Buy$59.00LowView Rating Details
11/7/2017Royal Bank of CanadaBoost Price TargetSector Perform -> Sector Perform$32.00 -> $37.00N/AView Rating Details
10/24/2017MizuhoReiterated RatingBuy$37.00N/AView Rating Details
10/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$44.00 -> $48.00N/AView Rating Details
10/6/2017Morgan StanleyBoost Price TargetEqual Weight$36.00 -> $39.00N/AView Rating Details
10/5/2017InstinetReiterated RatingBuy$37.00N/AView Rating Details
10/5/2017CowenReiterated RatingMarket Perform$30.00 -> $36.00N/AView Rating Details
10/4/2017BTIG ResearchBoost Price TargetBuy -> Buy$42.00 -> $45.00HighView Rating Details
9/29/2017BMO Capital MarketsReiterated RatingBuy$45.00LowView Rating Details
8/22/2017ArgusDowngradeBuy -> Hold$47.59 -> $29.39LowView Rating Details
5/22/2017BarclaysUpgradeEqual Weight -> Overweight$47.00 -> $50.00LowView Rating Details
4/18/2017Deutsche BankLower Price TargetBuy$52.00 -> $51.00LowView Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveN/AView Rating Details
10/10/2016Raymond James FinancialUpgradeMarket Perform -> Strong-Buy$57.00N/AView Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/AView Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00N/AView Rating Details
8/24/2016Bank of AmericaReiterated RatingBuy$70.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Mylan (NASDAQ:MYL) Earnings History and Estimates Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$1.42N/AView Earnings Details
11/6/2017Q3 2017$1.20$1.10$3.09 billion$2.99 billionViewN/AView Earnings Details
8/9/2017Q2 2017$1.18$1.10$3.00 billion$2.96 billionViewListenView Earnings Details
5/10/2017Q1 17$0.92$0.93$2.81 billion$2.72 billionViewN/AView Earnings Details
3/1/2017Q4 2016$1.42$1.57$3.18 billion$3.27 billionViewN/AView Earnings Details
11/9/2016Q3 2016$1.50$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.70$0.70$2.22 billion$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.70$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.63$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
10/26/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/28/2010Q2 2010$0.38$0.37ViewN/AView Earnings Details
4/29/2010Q1 2010$0.34$0.36ViewN/AView Earnings Details
2/25/2010Q4 2009$0.30$0.33ViewN/AView Earnings Details
10/29/2009Q3 2009$0.27$0.32ViewN/AView Earnings Details
7/30/2009Q2 2009$0.29$0.32ViewN/AView Earnings Details
4/30/2009Q1 2009$0.27$0.22ViewN/AView Earnings Details
2/19/2009Q4 2008$0.14$0.26ViewN/AView Earnings Details
10/30/2008Q3 2008$0.12$0.23ViewN/AView Earnings Details
8/6/2008Q2 2008$0.10$0.16ViewN/AView Earnings Details
5/8/2008Q1 2008$0.08$0.09ViewN/AView Earnings Details
2/27/2008Q4 2007($0.06)$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Mylan (NASDAQ:MYL) Earnings Estimates

2018 EPS Consensus Estimate: $5.35
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.09$1.09$1.09
Q2 20181$1.29$1.29$1.29
Q3 20181$1.41$1.41$1.41
Q4 20181$1.56$1.56$1.56
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Mylan (NASDAQ:MYL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 74.90%
Insider Trades by Quarter for Mylan (NASDAQ:MYL)
Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2018Heather M. BreschCEOSell75,000$45.00$3,375,000.00View SEC Filing  
6/9/2017Anthony MauroInsiderSell10,000$40.00$400,000.00140,653View SEC Filing  
6/9/2017Rajiv MalikPresidentSell25,000$40.00$1,000,000.00799,855View SEC Filing  
3/23/2017Laboratories AbbottMajor ShareholderSell44,000,000$41.60$1,830,400,000.00View SEC Filing  
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00828,318View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.5022,036View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.3013,384View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.001,872View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.001,872View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.801,334,306View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.3216,124View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.0031,365View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.1066,677View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.2110,322View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37171,251View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00289,117View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00293,418View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.0432,136View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.0023,389View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80133,373View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.0025,473View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.5082,296View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.0036,271View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.9532,136View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.0062,436View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.3268,971View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mylan (NASDAQ MYL) News Headlines

Source:
DateHeadline
Zacks Investment Research Upgrades Mylan (MYL) to "Hold"Zacks Investment Research Upgrades Mylan (MYL) to "Hold"
www.americanbankingnews.com - January 16 at 11:52 AM
How Teva Pharmaceutical Plans to Improve Financial ProfileHow Teva Pharmaceutical Plans to Improve Financial Profile
finance.yahoo.com - January 16 at 10:00 AM
H&Ms monkey ad isnt the first time celebs have yanked endorsements, but its rare - USA TODAYH&M's 'monkey' ad isn't the first time celebs have yanked endorsements, but it's rare - USA TODAY
www.usatoday.com - January 15 at 4:54 PM
Teva Pharmaceutical Focusing on Per Product Operating ProfitsTeva Pharmaceutical Focusing on Per Product Operating Profits
finance.yahoo.com - January 15 at 9:52 AM
Mylan Hits 80-Plus Relative Strength Rating BenchmarkMylan Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - January 12 at 4:45 PM
Mylan sees opportunity in rival Tevas weakness - MarketWatchMylan sees opportunity in rival Teva's weakness - MarketWatch
www.marketwatch.com - January 11 at 5:02 PM
Goldman rates Mylan tops in generic drug space, sees 14% upside ... - Seeking AlphaGoldman rates Mylan tops in generic drug space, sees 14% upside ... - Seeking Alpha
seekingalpha.com - January 11 at 5:02 PM
Goldman rates Mylan tops in generic drug space, sees 14% upside; shares ahead 3%Goldman rates Mylan tops in generic drug space, sees 14% upside; shares ahead 3%
seekingalpha.com - January 11 at 10:29 AM
Goldman Sachs Group Boosts Mylan (MYL) Price Target to $52.00Goldman Sachs Group Boosts Mylan (MYL) Price Target to $52.00
www.americanbankingnews.com - January 11 at 9:43 AM
Mylan (MYL) CEO Sells $3,375,000.00 in StockMylan (MYL) CEO Sells $3,375,000.00 in Stock
www.americanbankingnews.com - January 10 at 9:38 PM
BRIEF-Tax reform relatively neutral for Mylan-CFOBRIEF-Tax reform relatively neutral for Mylan-CFO
www.reuters.com - January 10 at 10:04 AM
Analysts’ Recommendations for MylanAnalysts’ Recommendations for Mylan
finance.yahoo.com - January 10 at 10:04 AM
Mylan CEO: We took care of the EpiPen problemMylan CEO: We took care of the EpiPen problem
finance.yahoo.com - January 9 at 4:58 PM
Mylan (MYL) Receives Consensus Rating of "Buy" from AnalystsMylan (MYL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 2:08 PM
Mylan (MYL) Completing Prior $1B Share Repurchase PlanMylan (MYL) Completing Prior $1B Share Repurchase Plan
www.streetinsider.com - January 9 at 9:55 AM
Biotech Analysis Central Pharma News: Allergans Restasis Trouble, Mylans Advance On Teva, Pfizers Alzheimers Exit - Seeking AlphaBiotech Analysis Central Pharma News: Allergan's Restasis Trouble, Mylan's Advance On Teva, Pfizer's Alzheimer's Exit - Seeking Alpha
seekingalpha.com - January 8 at 5:01 PM
Mylan To Close $1 Bln Share Repurchase PlanMylan To Close $1 Bln Share Repurchase Plan
www.nasdaq.com - January 8 at 10:10 AM
Mylan Sees RS Rating Improve To 75Mylan Sees RS Rating Improve To 75
finance.yahoo.com - January 5 at 4:40 PM
Plans to Slash Medical Costs in America Run Into Generic Drug ConcernsPlans to Slash Medical Costs in America Run Into Generic Drug Concerns
finance.yahoo.com - January 5 at 4:40 PM
Mylan (MYL) to Post FY2017 Earnings of $4.55 Per Share, Leerink Swann ForecastsMylan (MYL) to Post FY2017 Earnings of $4.55 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 5 at 7:50 AM
Mylan (MYL) PT Raised to $58.00Mylan (MYL) PT Raised to $58.00
www.americanbankingnews.com - January 4 at 10:28 AM
Mylan (MYL) Forecasted to Post Q1 2018 Earnings of $1.09 Per ShareMylan (MYL) Forecasted to Post Q1 2018 Earnings of $1.09 Per Share
www.americanbankingnews.com - January 4 at 10:16 AM
Mylan (MYL) PT Raised to $58 at Citi, Added To Citi US Focus List, Top Pick for 2018Mylan (MYL) PT Raised to $58 at Citi, Added To Citi US Focus List, Top Pick for 2018
www.streetinsider.com - January 4 at 9:54 AM
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
finance.yahoo.com - January 3 at 4:58 PM
 Brokerages Anticipate Mylan (MYL) Will Announce Quarterly Sales of $3.28 Billion Brokerages Anticipate Mylan (MYL) Will Announce Quarterly Sales of $3.28 Billion
www.americanbankingnews.com - January 3 at 8:30 AM
Drug companies may have shorted government more than $1 billion in Medicaid rebatesDrug companies may have shorted government more than $1 billion in Medicaid rebates
finance.yahoo.com - January 2 at 5:56 PM
Drug companies may have shorted government more than $1 billion in Medicaid rebatesDrug companies may have shorted government more than $1 billion in Medicaid rebates
finance.yahoo.com - January 2 at 5:56 PM
Leerink Swann Begins Coverage on Mylan (MYL)Leerink Swann Begins Coverage on Mylan (MYL)
www.americanbankingnews.com - January 2 at 5:18 PM
$1.40 Earnings Per Share Expected for Mylan (MYL) This Quarter$1.40 Earnings Per Share Expected for Mylan (MYL) This Quarter
www.americanbankingnews.com - January 1 at 11:24 AM
Mylan Adds to U.S. Womens Healthcare Portfolio With FDA ... - PR Newswire (press release)Mylan Adds to U.S. Women's Healthcare Portfolio With FDA ... - PR Newswire (press release)
www.prnewswire.com - December 29 at 4:50 PM
Mylan (MYL) Short Interest Up 10.0% in DecemberMylan (MYL) Short Interest Up 10.0% in December
www.americanbankingnews.com - December 29 at 1:58 AM
Biocon and Mylans Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner LibbsBiocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
www.prnewswire.com - December 29 at 1:55 AM
Mylan (MYL) Given a $41.00 Price Target by Cantor Fitzgerald AnalystsMylan (MYL) Given a $41.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 27 at 7:16 AM
Generic Alpha - A Mylan Story - Seeking AlphaGeneric Alpha - A Mylan Story - Seeking Alpha
seekingalpha.com - December 26 at 9:27 AM
Did Mylan NV (NASDAQ:MYL) Create Value For Investors Over The Past Year?Did Mylan NV (NASDAQ:MYL) Create Value For Investors Over The Past Year?
finance.yahoo.com - December 26 at 9:27 AM
Mylan tip of the iceberg, senator says as report suggests drug misclassifications cost taxpayers billions - Pittsburgh Business TimesMylan 'tip of the iceberg,' senator says as report suggests drug misclassifications cost taxpayers billions - Pittsburgh Business Times
www.bizjournals.com - December 22 at 10:06 AM
Mylan tip of the iceberg, senator says as report suggests drug misclassifications cost taxpayers billionsMylan 'tip of the iceberg,' senator says as report suggests drug misclassifications cost taxpayers billions
finance.yahoo.com - December 22 at 10:06 AM
Mylan to Present at the 36th Annual J.P. Morgan Healthcare ConferenceMylan to Present at the 36th Annual J.P. Morgan Healthcare Conference
www.prnewswire.com - December 20 at 12:37 PM
3 Top Generic Drug Stocks to Consider Buying Now3 Top Generic Drug Stocks to Consider Buying Now
finance.yahoo.com - December 20 at 10:02 AM
Mylan (MYL) Upgraded to Strong-Buy by BidaskClubMylan (MYL) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - December 19 at 6:46 AM
IBD Rating Upgrades: Mylan Flashes Improved Relative Price StrengthIBD Rating Upgrades: Mylan Flashes Improved Relative Price Strength
finance.yahoo.com - December 18 at 4:52 PM
Time For Big Pharma Step Up Before The Drug Price Debate Rises AgainTime For Big Pharma Step Up Before The Drug Price Debate Rises Again
finance.yahoo.com - December 18 at 10:18 AM
Zacks: Analysts Expect Mylan (MYL) Will Announce Quarterly Sales of $3.28 BillionZacks: Analysts Expect Mylan (MYL) Will Announce Quarterly Sales of $3.28 Billion
www.americanbankingnews.com - December 17 at 4:56 AM
Stock Traders Purchase Large Volume of Call Options on Mylan (MYL)Stock Traders Purchase Large Volume of Call Options on Mylan (MYL)
www.americanbankingnews.com - December 17 at 1:34 AM
Mylan (MYL) and NephroGenex (NRXGQ) Head to Head ReviewMylan (MYL) and NephroGenex (NRXGQ) Head to Head Review
www.americanbankingnews.com - December 16 at 3:26 AM
Head to Head Review: NephroGenex (NRXGQ) & Mylan (MYL)Head to Head Review: NephroGenex (NRXGQ) & Mylan (MYL)
www.americanbankingnews.com - December 15 at 7:10 PM
Mylan (MYL) Receives Consensus Recommendation of "Buy" from AnalystsMylan (MYL) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 15 at 11:42 AM
NephroGenex (NRXGQ) versus Mylan (MYL) Head to Head SurveyNephroGenex (NRXGQ) versus Mylan (MYL) Head to Head Survey
www.americanbankingnews.com - December 15 at 5:30 AM
Mylan (MYL) vs. NephroGenex (NRXGQ) Head to Head SurveyMylan (MYL) vs. NephroGenex (NRXGQ) Head to Head Survey
www.americanbankingnews.com - December 15 at 3:10 AM
Mylan (MYL) Says PTAB Institutes Inter Partes Review Against Sanofis Lantus PatentsMylan (MYL) Says PTAB Institutes Inter Partes Review Against Sanofi's Lantus Patents
www.streetinsider.com - December 14 at 5:28 PM

SEC Filings

Mylan (NASDAQ:MYL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mylan (NASDAQ:MYL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mylan (NASDAQ MYL) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.